安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAR 安飞士

盘前交易 04-23 05:51:05 EDT

102.09

+0.44

+0.43%

最高103.46	最低98.84	成交量63.53万
今开102.16	昨收101.65	日振幅4.55%
总市值36.21亿	流通市值17.64亿	总股本3,547万
成交额6,432万	换手率3.68%	流通股本1,727万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":102.09,"timestamp":1713816000000,"preClose":101.65,"halted":0,"volume":635272,"delay":0,"floatShares":17274134,"shares":35472745,"eps":42.08,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.44,"latestTime":"04-23 05:51:05 EDT","open":102.16,"high":103.46,"low":98.84,"amount":64318069.17096,"amplitude":0.04545,"askPrice":113,"askSize":1,"bidPrice":99.01,"bidSize":44,"shortable":3,"etf":0,"ttmEps":42.08,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713879000000},"adr":0,"adjPreClose":102.09,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":102.09,"preClose":102.09,"latestTime":"19:48 EDT","volume":6730,"amount":687066.33,"timestamp":1713829735575},"volumeRatio":0.7785856351109355},"requestUrl":"/m/hq/s/CAR","defaultTab":"news","newsList":[{"id":"2429156276","title":"欧盟委员会批准 CARVYKTI®用于复发和难治性多发性骨髓瘤患者的二线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2429156276","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2429156276?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:36","pubTimestamp":1713854160,"startTime":"0","endTime":"0","summary":"BCMA主要表达于恶性多发性骨髓瘤B细胞谱系、晚期B细胞和浆细胞的表面。2022年2月，西达基奥仑赛获得美国FDA批准上市，5月获得欧盟EC授予的附条件上市许可，9月获得日本MHLW批准上市，用于治疗复发或难治性多发性骨髓瘤成人患者，商品名为CARVYKTI。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4394792_ZH94792_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429158464","title":"强生(JNJ.US)&传奇生物CAR-T疗法再获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2429158464","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429158464?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:51","pubTimestamp":1713851483,"startTime":"0","endTime":"0","summary":"西达基奥仑赛是一种靶向B细胞成熟抗原的CAR-T疗法。2017年12月，强生旗下强生创新制药与传奇生物签订了全球独家许可和合作协议，以开发和商业化西达基奥仑赛。2022年2月，西达基奥仑赛获得美国FDA批准上市，5月获得EC授予的附条件上市许可，用于治疗复发或难治性多发性骨髓瘤成人患者，这些患者至少接受过3种前期疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313561587a4794c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313561587a4794c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429922286","title":"安飞士跌1.78% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2429922286","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429922286?lang=zh_cn&edition=full","pubTime":"2024-04-22 22:14","pubTimestamp":1713795241,"startTime":"0","endTime":"0","summary":"北京时间2024年04月22日22时14分，安飞士股票出现波动，股价急速下挫1.78%。最近的财报数据显示，该股实现营业收入120.08亿美元，净利润16.32亿美元，每股收益42.61美元，毛利39.27亿美元，市盈率2.38倍。安飞士股票所在的租赁服务行业中，整体涨幅为0.93%。消息层面，截至22时14分，《德银：维持Avis Budget Gr评级，由买入调整至买入评级, 目标价由202.00美元调整至183.00美元。》资讯为影响安飞士的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422221402861e7d9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422221402861e7d9b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429070942","title":"更新版 1-百时美施贵宝与 Cellares 签订价值 3.8 亿美元的 CAR-T 疗法供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2429070942","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429070942?lang=zh_cn&edition=full","pubTime":"2024-04-22 19:43","pubTimestamp":1713786237,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)    路透社4月22日 - 制药商百时美施贵宝  表示，已与合同制造商Cellares签署了一项价值3.8亿美元的协议，在美国、欧盟和日本生产其CAR-T细胞疗法。由于需求不断增长，这项合作将有助于百时美施贵宝扩大其生产能力。该公司今年 2 月表示，今年将在一些新的国家推出 CAR-T 血液癌症疗法 Abecma 和 Breyanzi。CAR-T疗法包括移除患者自身的T细胞--免疫系统的一个关键组成部分--对其进行工程改造，使其能够识别和攻击恶性细胞，然后重新注入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429694178","title":"百时美施贵宝与 Cellares 达成 3.8 亿美元 CAR-T 疗法供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2429694178","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429694178?lang=zh_cn&edition=full","pubTime":"2024-04-22 19:06","pubTimestamp":1713784005,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月22日 - 百时美施贵宝  和Cellares公司周一表示，他们已达成一项3.8亿美元的协议，为更多患者提供CAR-T细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428754599","title":"安飞士盘中异动 下午盘股价大跌5.05%报100.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428754599","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428754599?lang=zh_cn&edition=full","pubTime":"2024-04-19 02:30","pubTimestamp":1713465026,"startTime":"0","endTime":"0","summary":"北京时间2024年04月19日02时30分，安飞士股票出现异动，股价快速跳水5.05%。截至发稿，该股报100.03美元/股，成交量51.3498万股，换手率1.44%，振幅5.11%。最近的财报数据显示，该股实现营业收入120.08亿美元，净利润16.32亿美元，每股收益42.61美元，毛利39.27亿美元，市盈率2.38倍。安飞士股票所在的租赁服务行业中，整体跌幅为0.27%。该信息摘要如下：德银：维持Avis Budget Gr评级，由买入调整至买入评级, 目标价由202.00美元调整至183.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419023026792196fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419023026792196fc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428512650","title":"德银：维持Avis Budget Gr(CAR.US)评级，由买入调整至买入评级, 目标价由202.00美元调整至183.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428512650","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428512650?lang=zh_cn&edition=full","pubTime":"2024-04-19 00:45","pubTimestamp":1713458707,"startTime":"0","endTime":"0","summary":"德银：维持Avis Budget Gr(CAR.US)评级，由买入调整至买入评级, 目标价由202.00美元调整至183.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190045088b36c864&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190045088b36c864&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428370263","title":"CAR-T市场逼近千亿：国内企业保“生存”，跨国公司挣美金","url":"https://stock-news.laohu8.com/highlight/detail?id=2428370263","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428370263?lang=zh_cn&edition=full","pubTime":"2024-04-17 10:16","pubTimestamp":1713320219,"startTime":"0","endTime":"0","summary":"随着各大药企2023年财报出炉，市场发现全球CAR-T的市场销售正出现分化。而在国内，目前已有5款CAR-T产品同台竞争。市场预计Carvykti的销售额有望在明年突破10亿美元。其中，BMS的2款CAR-T疗法Abecma、Breyanzi在去年销售额总计8.36亿美元。作为全球首款获批CAR-T疗法，Kymriah在适应症扩展和制备工艺方面不及竞品成为其市场出现萎缩的原因之一。高价高成本显然是抑制国内CAR-T市场扩容的主要因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103699.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427759260","title":"安飞士盘中异动 下午盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427759260","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427759260?lang=zh_cn&edition=full","pubTime":"2024-04-13 02:38","pubTimestamp":1712947117,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日02时38分，安飞士股票出现波动，股价快速跳水5.01%。截至发稿，该股报114.98美元/股，成交量45.1208万股，换手率1.27%，振幅4.66%。安飞士股票所在的租赁服务行业中，整体跌幅为2.08%。消息层面，截至02时38分，安飞士股票正面舆情新闻比例100%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240413023837861e55ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240413023837861e55ef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425610426","title":"传奇生物CAR-T在美获批二线适应症 今年销售额有望破10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425610426","media":"经济观察网","top":-1,"share":"https://www.laohu8.com/m/news/2425610426?lang=zh_cn&edition=full","pubTime":"2024-04-07 21:18","pubTimestamp":1712495919,"startTime":"0","endTime":"0","summary":"经济观察网 记者 瞿依贤 经济观察网 记者 瞿依贤 4月6日，传奇生物宣布其CAR-T产品——西达基奥仑赛在美国获批用于复发或难治性多发性骨髓瘤患者的二线治疗。传奇生物合作伙伴强生预测，这款药今年的销售额会突破10亿美元。西达基奥仑赛自美国上市以后的累计销售额为6.3亿美元，其中2023年的销售额超过5亿美元。强生则预计，二线适应症在美国获批后，西达基奥仑赛今年的销售收入将突破10亿美元，未来的销售峰值会超过50亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425570126","title":"全球首个获批用于多发性骨髓瘤二线治疗的CAR-T，花落中国药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2425570126","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2425570126?lang=zh_cn&edition=full","pubTime":"2024-04-06 18:16","pubTimestamp":1712398560,"startTime":"0","endTime":"0","summary":"如何将CAR-T细胞疗法推向前线治疗，是每家CAR-T企业试图努力的方向。由此西达基奥仑赛也成为全球首个且唯一获批多发性骨髓瘤二线治疗的CAR-T产品。西达基奥仑赛是传奇生物的主打产品，该药首度于2022年2月28日在美国获批上市，用于治疗既往接受过至少四线治疗的复发或难治性多发性骨髓瘤成人患者，这是首款走出国门的中国原创CAR-T细胞治疗药物。该药是全球范围内第7款上市的CAR-T产品，也是第2款靶向BCMA的CAR-T产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040618165787e4a72e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040618165787e4a72e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425259314","title":"BUZZ-赫兹下滑，高盛转为看跌，并上调安飞士评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2425259314","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2425259314?lang=zh_cn&edition=full","pubTime":"2024-04-05 00:14","pubTimestamp":1712247264,"startTime":"0","endTime":"0","summary":"    4月4日 - ** 在高盛将租车公司评级从 \"中性 \"下调至 \"卖出 \"后，赫兹  股价周四下跌4.1%，报7.32美元。** 赫兹今年早些时候表示，它将出售  大约 20,000 辆电动汽车，包括特斯拉   ，约占其全球电动汽车车队的三分之一，并将选择汽油动力汽车** 与此相反，高盛将同行安飞士预算集团  的评级提升至 \"中性\"，并将其股票交易价格从118美元上调至130美元(，这也是该公司股价的街市最低点。** 尽管HTZ和CAR在盘中走高，但在2024年都下跌了30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424382663","title":"IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2424382663","media":"StreetInsider","top":-1,"share":"https://www.laohu8.com/m/news/2424382663?lang=zh_cn&edition=full","pubTime":"2024-04-04 09:54","pubTimestamp":1712195640,"startTime":"0","endTime":"0","summary":"SHANGHAI, NANJING, China and SAN JOSE, Calif., April 4, 2024 /PRNewswire/ -- IASO Biotechnology , a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercialising innovative cell therapy and antibody products, is pleased to announce that the Investigational New Drug  application for its BCMA CAR-T  has been approved by the U.S. Food and Drug Administration  for use in U.S. clinical trials for generalised myasthenia gravis . The Chinese IND for this indication of Equecabtagene Autoleucel was approved by the NMPA in January this year.PK/PD: Eque-cel expanded well after infusion. Anti-AChR antibodies, anti-Titin antibodies, and anti-MuSK antibodies decreased rapidly and maintained at very low levels in both subjects after infusion. B cells and plasma cells decreased to undetectable levels in both subjects within 2 months after infusion and then recovered gradually. At 18 months post-infusion, the B cells of both subjects had returned to normal levels, wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23025675","is_publish_highlight":false,"gpt_icon":0},{"id":"2422113941","title":"上市连年亏损 CAR-T产品遭遇致癌和停产的风波 科济药业“正在努力”","url":"https://stock-news.laohu8.com/highlight/detail?id=2422113941","media":"华夏时报","top":-1,"share":"https://www.laohu8.com/m/news/2422113941?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:05","pubTimestamp":1711609544,"startTime":"0","endTime":"0","summary":"3月26日，科济药业披露2023年业绩报告，公司净亏损7.48亿元，上年同期亏损8.92亿元。科济药业自上市以来一直处于亏损状态，不过与2022年相比，去年亏损收窄1.44亿元。公告称，公司减亏的主要原因有以股份为基础的薪酬减少，研发开支减少及行政开支减少以及年度的汇兑亏损减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403283027839338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283027839338.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422060320","title":"科济药业发布2023年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2422060320","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422060320?lang=zh_cn&edition=full","pubTime":"2024-03-27 08:30","pubTimestamp":1711499400,"startTime":"0","endTime":"0","summary":"上海2024年3月27日 /美通社/ -- 科济药业，一家主要专注于治疗血液恶性肿瘤和实体瘤的创新CAR-T细胞疗法公司，发布了2023年度业绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4371008_ZH71008_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422077635","title":"高位跌停，大牛股果然“快速下跌”！CAR-T疗法新突破，自身免疫性疾病治愈有希望，这些概念股砸出“深坑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2422077635","media":"数据宝","top":-1,"share":"https://www.laohu8.com/m/news/2422077635?lang=zh_cn&edition=full","pubTime":"2024-03-26 12:27","pubTimestamp":1711427220,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　CAR-T疗法市场前景获业界看好。　　3月26日早盘，多只热门股高位跳水。艾艾精工跌停板开盘，盘中短暂被撬开，随后快速封跌停，截至午间收盘，跌停板封单达到7.66万手。公司股票击鼓传花效应明显，存在非理性炒作风险，随时有快速下跌的可能。　　CAR-T疗法利用名为T细胞的免疫细胞。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2024-03-26/doc-inaprmtv6721431.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2024-03-26/doc-inaprmtv6721431.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420208019","title":"BUZZ-Avis 在美国银行将其评级定为 \"买入 \"后反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2420208019","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420208019?lang=zh_cn&edition=full","pubTime":"2024-03-20 01:16","pubTimestamp":1710868614,"startTime":"0","endTime":"0","summary":"    3月19日 - ** 周二，Avis Budget Group  股价上涨6.1%，报114.67美元，此前美国银行给予该公司 \"买入 \"评级。** Babcock 将赫兹全球控股公司  的评级定为 \"中性\"，目标价为 9 美元，称该公司的盈利增长可能会受到 2024 年和 2025 年车辆利息支出 \"大幅增长 \"的抑制。** 对于 HTZ，所有 9 位分析师都将其股票评级为 \"持有\"，PT 中位数为 9.50 美元。** CAR 和 HTZ 今年以来的跌幅均超过 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":-0.0877},{"period":"1month","weight":-0.1003},{"period":"3month","weight":-0.3921},{"period":"6month","weight":-0.3893},{"period":"1year","weight":-0.4223},{"period":"ytd","weight":-0.4241}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0412},{"period":"3month","weight":0.0306},{"period":"6month","weight":0.1968},{"period":"1year","weight":0.2123},{"period":"ytd","weight":0.0514}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.是一家在特拉华州成立，总部位于新泽西州帕西帕尼市的公司。艾维士·巴吉集团为全球企业和消费者提供汽车和卡车租赁和配套服务。该公司经营着两家全球汽车租赁行业中最知名的品牌Avis和Budget。 Avis是一家领先的汽车租赁供应商，定位于服务旅游业的优质商业和休闲领域，而Budget是一家领先的汽车租赁供应商，业务主要集在该行业中更具价值意识的部分。该公司是领先的汽车租赁运营商，在北美，澳大利亚，新西兰和其他地区都有业务服务，该公司授权在世界各地以Avis和Budget品牌经营的国家就有超过180个多个。该公司通常在机场汽车租赁收入中占有主要份额，并运营着美国主要的卡车租赁业务之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.012765},{"month":2,"riseRate":0.642857,"avgChangeRate":0.055699},{"month":3,"riseRate":0.642857,"avgChangeRate":0.042142},{"month":4,"riseRate":0.642857,"avgChangeRate":0.015964},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.021859},{"month":6,"riseRate":0.538462,"avgChangeRate":0.01495},{"month":7,"riseRate":0.615385,"avgChangeRate":0.048264},{"month":8,"riseRate":0.461538,"avgChangeRate":0.008638},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.037867},{"month":10,"riseRate":0.769231,"avgChangeRate":0.153852},{"month":11,"riseRate":0.692308,"avgChangeRate":0.064181},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.03046}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}